Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW406381 · 5 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| Subjects receiving GW406381 | EXPERIMENTAL | Subjects will receive single oral dose of 20 milligram (mg) of GW406381. |
| Name | Type | Description |
|---|---|---|
| GW406381 | DRUG | - |
Inclusion criteria: * Rheumatoid arthritis (RA) for at least 12 months. * Required a non-steroidal anti-inflammatory drug (NSAID) or COX-2 inhibitor for RA for at least 5 out of 7 days of each week for the 4 weeks prior to screening. Exclusion criteria: * Any history of cardiovascular disease (e....
GW406381 is an investigational small molecule drug developed by GSK plc for pain and inflammatory conditions. It has been studied in arthritis, rheumatoid arthritis, osteoarthritis of the knee, dental pain, and hyperalgesia. It reached Phase 3 clinical development but is not described as approved.
GW406381 has been studied for pain and inflammatory conditions including osteoarthritis of the knee, rheumatoid arthritis, dental pain following third molar tooth extraction, and hyperalgesia associated with peripheral nerve injury. These studies were conducted in adults, and the drug remains investigational.
GW406381 targets PTGS2, also known as cyclooxygenase-2 or COX-2. It acts as an inhibitor of this enzyme. PTGS2 inhibition is the mechanism behind its investigation for pain and inflammatory conditions such as osteoarthritis and dental pain.
GW406381 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical trials evaluating the drug in osteoarthritis of the knee, dental pain, peripheral nerve injury, and hepatic impairment.
GW406381 reached Phase 3 clinical development. A Phase 3 trial evaluated it in adults with osteoarthritis of the knee, and another Phase 3 trial studied it in dental pain following third molar tooth extraction. It is an investigational drug and is not described as approved.
GW406381 has been studied in completed trials including NCT00120900 in osteoarthritis of the knee, NCT00114049 in dental pain after third molar extraction, NCT00279032 in patients with peripheral nerve injury, and NCT00373243 in volunteers with moderate hepatic impairment. All four trials are listed as completed.